(Q40920731)

24 September 2017

1 reference

title

Pharmacology of immunosuppressive medications used in renal diseases and transplantation (English)

1 reference

24 September 2017

1 reference

de Mattos AM

1

1 reference

24 September 2017

Olyaei AJ

series ordinal

2

1 reference

24 September 2017

Bennett WM

series ordinal

3

1 reference

24 September 2017

publication date

1 November 1996

1 reference

American Journal of Kidney Diseases

24 September 2017

published in

1 reference

24 September 2017

volume

28

1 reference

24 September 2017

issue

5

1 reference

24 September 2017

page(s)

631-667

1 reference

The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine.

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Enzymes of the purine metabolism: inhibition and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The therapeutic use of azathioprine in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

IMP dehydrogenase inhibitors as immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Azathioprine metabolism in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Azathioprine-induced leukopenia--clinical significance in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Etiology of Liver Disease in Renal-Transplant Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Liver disease in recipients of long-functioning renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Azathioprine-associated interstitial pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Immunosuppressive drug therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Alkylating agents and purine analogues in primary glomerulonephritis with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Single-dose pharmacokinetics of the new immunosuppressant RS-61443 in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Immunosuppressive activity of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclophosphamide toxicity. Characterising and avoiding the problem

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Methylprednisolone and cyclophosphamide pulse therapy in crescentic glomerulonephritis: safety and effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Ifosfamide-induced renal tubular defects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclophosphamide pulse therapy in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The natural history and therapy of idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

AL amyloidosis: therapeutic response in two patients with renal involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Experiences with renal homotransplantation in the human: report of nine cases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Diurnal variation in prednisolone kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Prednisolone disposition in steroid-dependent asthmatic children.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Pharmacokinetics of prednisolone in children with nephrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Various modes of gene regulation by nuclear receptors for steroid and thyroid hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Structure and function of the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Some molecular mechanisms of glucocorticoid action

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

An overview of glucocorticoid anti-inflammatory actions

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Regulation of transforming growth factor-beta 1 gene expression by glucocorticoids in normal human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cytokine regulation of group II phospholipase A2 expression in glomerular mesangial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Prednisone and prednisolone bioavailability in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The Absence of Effect of Azathioprine on Prednisolone Pharmacokinetics Following Maintenance Prednisone Doses in Kidney Transplant Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Hyperlipidemia in renal transplant recipients: natural history and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children posttransplantation in the cyclosporine era.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cellular regulatory mechanisms that may underlie the effects of corticosteroids on bone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

New Glucocorticoids. Mechanisms of Immunological Activity at the Cellular Level and in the Clinical Setting

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Potency ratio--a brief synopsis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Differential effect of glucocorticoids on calcium absorption and bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Steroid therapy in primary glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Long-term follow-up of aggressively treated idiopathic rapidly progressive glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Meta-analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger's disease)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Treatment and monitoring of systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Pharmacokinetic drug interactions with cyclosporin (Part I).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Pharmacokinetic drug interactions with cyclosporin (Part II).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Do we know the site of action of cyclosporin?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The mechanism of action of cyclosporin A and FK506

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The mechanism of action of FK-506 and cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The effects of cyclosporin A on non-T cell components of the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporin A inhibits CD40 ligand expression in T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Effects of cyclosporine-A and cyclosporine-G on ADP-stimulated aggregation of human platelets.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporine-associated chronic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporine-induced renal dysfunction in experimental animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

1 reference

7 January 2021

The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Evidence that alterations in renal metabolism and lipid peroxidation may contribute to cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

A prospective study of renal structure and function in psoriasis patients treated with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Hemolytic uremic syndrome in renal allografted patients treated with cyclosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Hypertension and kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Role of endothelin in cyclosporine-induced glomerular dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cellular expression of angiotensin type-1 receptor mRNA in the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporine-induced hypertension after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporin in therapeutic doses increases renal allograft vascular resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporin A inhibits endothelium-dependent, prostanoid-induced relaxation in human subcutaneous resistance vessels.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Vascular mechanisms of cyclosporin-induced hypertension in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporine A induced remission of relapsing nephrotic syndrome in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Cyclosporin A treatment of severe steroid resistant nephrotic syndrome in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

FK-506--a novel immunosuppressant

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Rapamycin (sirolimus, rapamune).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

ATG--a polyclonal sledgehammer?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

OKT3-induced cytokine mRNA expression in human peripheral blood mononuclear cells measured by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Mechanism of T lymphocyte activation by OKT3 antibodies. A general model for T cell induction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Sequestration of labelled granulocytes in the lungs following administration of OKT3 is dose-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Encephalopathy associated with OKT3 administration. Possible interaction with indomethacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Complications and monitoring of OKT3 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

A randomized clinical trial of induction therapy with OKT3 in kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Monoclonal antibodies in organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Future of monoclonal antibodies in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Human monoclonal antibodies: recent achievements

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Prevention of nitric oxide synthase induction in vascular smooth muscle cells by microtubule depolymerizing agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Potential role of colchicine in the prevention of cast nephropathy from Bence Jones proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Colchicine and secondary amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Reversal of the Nephrotic Syndrome by Colchicine in Amyloidosis of Familial Mediterranean Fever

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Colchicine and mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Is There a Rational Use for n-3 Fatty Acids (Fish Oils) in Clinical Medicine?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Omega-3 fatty acid content of the US food supply

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

n-3 fatty acids and renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

n-3 fatty acids reduce proteinuria in patients with chronic glomerular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Fish oil has protective and therapeutic effects on proteinuria in passive Heymann nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Effects of dietary fish oil on renal insufficiency in rats with subtotal nephrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Very long chain n-3 and n-6 polyunsaturated fatty acids inhibit proliferation of human T-lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

The absorption of fish oils and concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Fish oil in lupus nephritis: clinical findings and methodological implications

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Ketoconazole to reduce the need for cyclosporine after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990246-2

7 January 2021

10.1016/S0272-6386(96)90246-2

Identifiers

DOI

1 reference

24 September 2017

1 reference